Eugia US LLC, formerly Auro Medics Pharma LLC, is recalling one lot of an injectable antibiotic after a glass particle was found inside a vial. The company announced the recall Nov. 6, 2026, and the U.S. Food and Drug Administration posted the notice Nov. 9, 2026.
The recall covers lot number 3VM26026A of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL, sold in single-dose vials. The recall is at the hospital, healthcare facility and user level. Eugia, based in East Windsor, New Jersey, said it shipped the entire lot to wholesalers across the country from Sept. 2, 2026, through Sept. 15, 2026.
Vancomycin is an antibacterial drug used in adults and children, including newborns. According to the company, it treats bloodstream infection (septicemia), infection of the heart lining and valves (infective endocarditis), skin, bone and lower respiratory tract infections.
The company said use of vials containing glass particles could cause serious harm. It listed blocked or clotted blood vessels, a life-threatening blood clot in the lungs, permanent organ damage and death. It also listed vein irritation, inflammatory reactions, worsening of existing infections and allergic reactions. Eugia said newborns, infants and patients with weakened organ function may be more susceptible. The company said it has received no reports of adverse events related to the recall.
The vials can be identified by the product name on the carton, which carries National Drug Code (NDC) 55150-471-10, and on the vial label, which carries NDC 55150-471-01. The lot number is 3VM26026A and the expiration date is July 2028.
Eugia said it is notifying distributors and customers by recall letter and arranging returns or replacements. Wholesalers, hospitals, pharmacies, institutions and doctors with the lot should stop using it and quarantine it immediately. Anyone who passed the lot along should notify those accounts, and hospitals should tell their healthcare professionals.
Consumers with medical questions or an adverse event to report can call Eugia at 1-866-850-2876, option 2, from 8 a.m. to 5 p.m. Eastern time, Monday to Friday, or email pvg@aurobindousa.com. Questions about returns go to Qualanex at 1-800-505-9291 or recall@qualanex.com. The company advised patients with problems possibly linked to the drug to contact a physician or healthcare provider.
Problems can also be reported to the FDA’s MedWatch program online, by mail or by fax. The company said the recall is being conducted with the FDA’s knowledge.
